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BACKGROUND AND PURPOSE:  
 
Cerebrospinal fluid (CSF) tau and neurofilament light chain (NF-L) proteins have proved to be 




The present study included 132 autopsy cases with rapidly progressive neurological syndromes, 
including Alzheimer disease (AD) (21), sporadic (65) and genetic (21) Creutzfeldt-Jakob 
disease (CJD), 25 cases with vascular, neoplastic and inflammatory alterations, and additionally 
18 healthy control individuals. CSF tau and NF-L concentrations were measured by enzyme-
linked immunosorbent assay. Plasma tau and NF-L concentrations were measured using ultra-




Plasma and CSF tau (R = 0.59, P < 0.001) and NF-L (R = 0.69, P < 0.001) levels correlated 
significantly (Spearman test). Plasma tau and NF-L levels were significantly higher in all 
disease groups compared to healthy controls (P < 0.001). Receiver operating characteristic 
curves were used and area under the curve values for comparisons with controls were 0.82 
(AD), 0.94 (sporadic CJD), 0.92 (genetic CJD) and 0.83 (other neurological disorders) for 
plasma tau and 0.99, 0.99, 1.00 and 0.96 for plasma NF-L, respectively. Molecular subtyping 
of sporadic CJD showed a strong effect (linear logistic regression) on plasma tau (P < 0.001) 
but not NF-L levels (P = 0.19). 
 
CONCLUSION:  
Plasma tau and NF-L concentrations are strongly increased in CJD and show similar 
diagnostic performance to the corresponding CSF measure. Molecular subtypes of sporadic 
CJD show different levels of plasma tau. Although not disease-specific, these findings support 




















Neurodegenerative diseases are characterized by progressive loss of neurons and deposition of 
pathological forms of proteins predominantly in the central nervous system. Current molecular 
pathological classification of neurodegenerative disease is therefore protein-based (14). The 
most important proteins, such as tau, -synuclein, transactive response (TAR) DNA-binding 
protein 43 (TDP-43), amyloid- (A), prion protein (PrP) are targets for body-fluid based 
biomarker development (14). In the diseased brain these proteins show several biochemical 
modifications (14); therefore either the physiological or the modified forms are selected for in 
vivo tests. Although markers are emerging detecting total and pathological forms of -synuclein 
(34) or disease-associated PrP (8, 22), currently, the most widely applied tests focusing on 
neurodegeneration-associated proteins are used for supporting the clinical diagnosis of 
Alzheimer disease (AD). These include the examination of total and phosphorylated (p181) tau 
and A levels and have relevance in the context of defining preclinical AD (7). Currently, these 
markers are analysed using the cerebrospinal fluid (CSF). However, most of the patients are 
seen by primary care doctors, therefore there is a strong need for blood-based tests (31).  
 
Biomarker modelling of AD emphasizes the importance of total tau as a marker of 
neurodegeneration (11). Indeed, neurodegeneration-related proteins are important for disease-
classification even in the context of frequent concomitant pathologies (27), however, the 
relevance of biomarkers reflecting the dynamics of neuronal degeneration remains of high 
value. In particular, these may allow assessment of prognosis or response to potential 
therapeutic efforts. Measurement of CSF total tau has proved to be a reliable marker of neuronal 
damage. Indeed, the most widely used surrogate markers for the clinical diagnosis of the most 
frequent human prion disease sporadic Creutzfeldt-Jakob disease (CJD) includes protein 14-3-
3 and total tau (18, 35). These show altered levels in genetic CJD as well (18). Furthermore, 
recent studies emphasize that there might be differences between molecular subtypes of 
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sporadic CJD (10). Molecular subtypes of sporadic CJD are distinguished based on the 
polymorphic codon 129 of the prion protein gene (PRNP) and types of protease-resistant PrP 
(26). Detection of total PrP (6) and -synuclein (20) has been recently added to the list of 
biomarkers helpful in the differential diagnosis of rapidly progressive dementias.  
 
A further, potentially relevant biomarker of neuronal damage is neurofilament light chain (NF-
L). This has been reported already in 1996 to be increased in several neurodegenerative and 
non-neurodegenerative conditions (30). Since NF-L is expressed in myelinated axons, studies 
focused on multiple sclerosis (37), furthermore, increased levels have been reported in 
traumatic brain injury (33). Importantly, recent studies suggest that NF-L can be reliably 
evaluated in the serum and can reflect disease intensity (3, 19, 29). Recent studies have shown 
that total tau levels can be also measured in the plasma (38), although on an individual level 
they are not helpful, e.g., in the diagnostics of AD (21).  
 
Based on the aforementioned studies, we hypothesized that the measurement of plasma tau and 
NF-L concentrations can be useful to support the diagnosis of human prion diseases. Therefore, 
we evaluated a cohort of neuropathologically classified CJD cases and compared with non-
diseased controls and with a wide range of disorders defined by neuropathological 
examinations. Our study supports the concept that tau and NF-L concentrations can be reliably 
measured in plasma and that they probably reflect ongoing neuronal damage. They show similar 
diagnostic performance as their corresponding CSF measure but are not disease-specific.  
 
Material and methods 
Case selection and samples  
The present study included 150 autopsy cases of neuropathologically confirmed AD (21 cases), 
sporadic CJD (65 cases), genetic CJD (21 cases with the E200K PRNP mutation) and cases 
with a wide range of neuropathological alterations, including cerebrovascular disease, 
inflammation (meningoencephalitis), PART, or Lewy body pathology (Table 1). Vascular and 
inflammatory lesions, tauopathies, Lewy body pathology (5) and neurofibrillary degeneration 
were (1, 4) documented and staged for all cases (Table 1). Tauopathy included argyrophilic 
grain disease or progressive supranuclear palsy type pathology (13). Molecular subtypes of 
sporadic CJD were defined following the classification by Parchi and colleagues (25, 26). 
Further neurodegenerative disorders and proteinopathies were excluded (16). In addition, 18 
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healthy control individuals were included. The controls had no subjective symptoms of 
cognitive dysfunction and were normal upon clinical neurological and psychiatric examination. 
 
Of all the neuropathologically examined patients, CSF samples had previously been submitted 
for routine analysis of 14-3-3 protein (in the frame of surveillance for prion diseases). Together 
with plasma samples prepared from blood sent in EDTA tubes supernatants were stored at -
80°C. This allowed us the investigation of CSF in combination with autopsy material from the 
same patient. The study was approved by the ethics committee of the Medical University of 
Vienna (Nr. 397/2011). 
Analysis of tau and neurofilament in the plasma and CSF samples 
CSF levels of total tau protein were measured using the INNOTEST ELISA (Fujirebio Europe, 
Ghent, Belgium), while NF-L levels were measured by the NF-light® ELISA kit 
(UmanDiagnostics AB, Umeå, Sweden). Plasma tau was measured using the Human Total Tau 
kit (Quanterix, Lexington, MA) on the Simoa HD-1 analyzer (CE marker). This assay differ 
from the previously published Simoa tau assay (28) in that it is based on different antibodies; 
one monoclonal antibody for capture that reacts with a linear epitope in the mid-region of tau, 
and one detection antibody that reacts with a linear epitope in the N-terminal region of T-tau. 
NF-L concentrations in blood were measured using the same monoclonal antibodies and 
calibrator as in the CSF assay, but the assay was transferred onto the Simoa platform using a 
homebrew kit (Quanterix, Lexington, MA, USA), as previously described (9). All CSF and 
plasma measurements were performed in one round of experiments using one batch of reagents 
by board-certified laboratory technicians who were blinded to clinical data. 
 
Statistical analysis 
Kruskal-Wallis (K-W) and Mann-Whitney (M-W) tests were used to compare different study 
groups. Linear logistic regression tests were performed to evaluate the effect of 
clinicopathological variables. Receiver-Operating-Characteristic (ROC) curves were used to 
evaluate the specificity and sensitivity of the tests used. For statistical analyses, we used SPSS 
Statistics (V23.0, SPSS Inc., Chicago, IL, USA). 
 
Results 
Plasma tau and NF-L levels correlate well with CSF tau and NF-L levels 
CSF tau levels were higher than plasma tau levels (CSF/plasma tau, mean: 779.1, range: 11.39-
10076.9). For the total cohort (n=93) Spearman correlation test revealed a strong correlation 
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between plasma and CSF tau (R=0.59, p<0.001) and NF-L (R: 0.69, p<0.001). CSF tau levels 
correlated with CSF NF-L (R=0.42, p<0.001) and plasma tau levels with plasma NF-L (0.50, 
p<0.001). CSF tau correlated with plasma NF-L (R: 0.34, p=0.001) but CSF NF-L levels did 
not correlate with plasma tau levels (R: 0.16, p=0.12). When different disease groups were 
evaluated separately, similar results were seen for sporadic CJD, while for AD, genetic CJD 
and other neurological diseases not all of these were significant (Table 2). 
 
We then evaluated whether age, gender and time interval from sampling to death (i.e., autopsy 
cohort) had any effect on these variables. We did not find any difference between men and 
women (M-W test, p>0.2 for all variables). Spearman correlation test revealed a negative 
correlation between age and CSF NF-L levels in the autopsy cohort (n= 93, R= - 0.22, p= 0.03). 
However, in a linear logistic regression model with diagnostic grouping and age added to the 
model this was not significant (p=0.1). Indeed, when evaluated in disease groups, age correlated 
inversely with CSF NF-L levels only in the sporadic CJD group (n=46, R= - 0.32, p=0.02). 
Importantly, the time interval from sampling to death (i.e., the whole autopsy cohort pooled) 
negatively correlated with CSF tau (R= - 0.26, p=0.01), plasma tau (R= -0.38, p<0.001) and 
plasma NF-L levels (R= - 0.18, p=0.03). Linear logistic regression test with diagnostic grouping 
and time interval to death added to the model, did not confirm an effect of time interval from 
sampling to death (p>0.07 for all). When diagnostic groups were evaluated separately, this time 
interval correlated negatively only in AD (plasma tau, R= - 0.46, p=0.03), sporadic CJD (plasma 
tau, R= -0.54, p<0.001; CSF tau, R= -0.3, p=0.04) and in genetic CJD (CSF tau, R= - 0.57, 
p=0.03). Braak NFT and Lewy-related pathology stages did not show any effect on these 
variables. 
 
Elevated plasma and CSF tau levels characterize AD and CJD cases  
When evaluating plasma tau levels, K-W test revealed significant differences between cases 
(p<0.0001) (Fig. 1A). High levels were observed in sporadic CJD, which was significantly 
(p<0.001) higher when compared to all other groups (M-W test) except to genetic CJD cases. 
Indeed, the mean plasma tau level in sporadic CJD cases showed more then ten-fold increase 
as compared to healthy controls and also prominently increased when compared to other 
neurological diseases (2.46-fold increase) or AD (2.28-fold increase). Plasma tau levels did not 
distinguish genetic CJD cases from other neurological diseases (p=0.08) but did from AD cases 
(p=0.03). Importantly, all disease groups showed significantly higher levels than the healthy 
control group (p>0.001). The mean plasma tau level in AD was 4.45-fold higher then in controls 
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(Fig. 1A). The highest levels of plasma tau (> 6 pg/ml) leading to an increased mean plasma 
tau value in the group of other neurological diseases were detected in single cases with i) 
cerebral lymphoma, ii) meningeal carcinomatosis, iii) severe ischemic/hypoxic 
panencephalopathy, iv) severe tick-borne encephalitis with ischemic/hypoxic brain damage, v) 
severe limbic encephalitis, and vi) multiple brain infarcts. On the other hand, cases with 
vascular encephalopathy including lacunar infarcts or strategic thalamus infarct, neurosyphilis, 
granulocytic meningoencephalitis, glioblastoma, or metabolic encephalopathy did not show 
high levels. 
 
Next we evaluated the sensitivity and specificity of plasma tau levels using ROC curves. Area 
under the curve (AUC) for comparisons with AD revealed the following results: i) 0.821 (95% 
CI: 0.69-0.95) for comparison with healthy controls (Fig. 2A) and ii) 0.453 (95% COI: 0.28-
0.62) for comparison with other neurological diseases. The AUC was i) 0.939 (95% COI: 0.89-
0.98) when comparing sporadic CJD to healthy controls (Fig. 2B); ii) 0.756 (95% COI: 0.63-
0.87) when comparing sporadic CJD to AD; iii) 0.722 (95% COI: 0.60-0.83) when comparing 
sporadic CJD to the group of other neurological diseases; and iv) 0.57 (95% COI: 0.43-0.71) 
when comparing sporadic to genetic CJD. AUCs for comparisons with genetic CJD revealed 
the following results: i) 0.918 (95% COI: 0.83-1.0) for comparison with healthy controls (Fig. 
2C); ii) 0.694 (95% COI: 0.53-0.85) for comparison with AD; and iii) 0.651 (95% COI: 0.48-
0.81) for comparison with the group of other neurological diseases. Finally comparing other 
neurological diseases and healthy controls (Fig. 2D) revealed an AUC of 0.829 (95% COI: 
0.70-0.95). 
 
When evaluating CSF tau levels for the autopsy cohort, similar trends were observed (Fig. 1B) 
although the AUC was higher in comparisons with sporadic and genetic CJD (Table 3).  
 
Elevated plasma and CSF NF-L levels in various diseases 
 
When evaluating plasma NF-L levels, K-W test revealed significant differences between cases 
(p<0.0001) (Fig. 1C). All diseased groups showed higher levels than controls (other 
neurological disease 27-fold, AD 12-fold, sporadic CJD 8-fold and genetic CJD 7-fold increase 
of mean value). The highest levels were observed in a few cases of the group of other 
neurological diseases; these were the same as those showing the highest plasma tau levels. 
Indeed, these cases with severe brain damage showed 10-100 times higher values as the normal 
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controls. M-W test revealed significant differences only for the comparisons with healthy 
controls (i.e., versus diseased controls, AD, sporadic and genetic CJD; all p<0.001).  
 
Next we evaluated the sensitivity and specificity of plasma NF-L levels using ROC curves 
(Table 3). The AUC was i) 0.992 (95% COI: 0.98-1.0) for the comparison of sporadic CJD and 
healthy controls; ii) 1.0 (95% COI: 1.0-1.0) for the comparison of genetic CJD and healthy 
controls; iii) 0.992 (95% COI: 0.97-1.0) for the comparison of AD and healthy controls, and iv) 
0.96 (95% COI: 0.90-1.0) comparing diseased and healthy controls. The AUC was i) 0.497 
(95% COI: 0.30-0.69) when comparing sporadic CJD to diseased controls; and ii) 0.657 (95% 
COI: 0.48-0.83) when comparing sporadic CJD to AD. AUCs for comparisons with genetic 
CJD revealed the following results: i) 0.705 (95% COI: 0.50-0.90) for comparison with AD; 
and ii) 0.520 (95% COI: 0.30-0.873) for comparison with diseased controls. Comparison of 
diseased controls to AD revealed an AUC of 0.576 (95% COI: 0.36-078). 
 
When evaluating CSF NF-L levels for the autopsy cohort, similar trends were observed (Fig. 
1D and Table 3). However, here further comparisons were significant as follows: i) sporadic 
versus genetic CJD (p=0.041); ii) sporadic CJD versus AD (p=0.002); iii) genetic CJD versus 
AD (p<0.001); and iv) diseased controls versus AD (p=0.036). 
 
The effect of molecular subtyping on tau and NF-L levels in sporadic CJD cases 
Linear logistic regression test indicated that molecular subtypes of sporadic CJD has a strong 
effect on the plasma (p=0.001) but not on CSF (p=0.3) tau levels, the first remaining significant 
(p=0.002) after the adjustment for Braak NFT stage and the time interval between sampling and 
death. Regarding plasma NF-L levels, molecular subtyping of sporadic CJD did not show a 
significant effect (p=0.19).  
 
Plasma tau levels were highest in the MM/MV type 1 and MM type 1+2 subtypes. M-W test 
revealed significantly higher values of plasma and CSF tau levels for most of the molecular 
subtypes when compared to the MV type 2 kuru plaque type sporadic CJD cases (Figs.1E, F).  
NF-L plasma and CSF levels showed similar patterns, though less comparisons were significant 
(Figs. 1G, H). In ROC curve analysis for plasma tau MM/MV type cases compared to MV type 
2K cases showed an AUC of 0.990 (95% COI 0.96-1.0) and 0.874 (95% COI 0.74-1.0) when 
compared to VV type 2 cases. Importantly, the lower tau and NF-L levels in MV type 2K cases 
were still higher when compared to non-diseased controls (M-W test: CSF tau, CSF and plasma 
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NF-L: p<0.001; plasma tau: p =0.1), however, plasma tau and NF-L levels were not 





The identification of proteins related to specific neurodegenerative diseases has opened new 
avenues for disease classification and biomarker development (14, 15). While there are efforts 
to detect disease-associated protein modifications in the blood (12, 34, 36), markers that reflect 
neuronal degeneration may be more tangible. In particular, those might be used to predict 
prognosis, clinical outcome (32), and eventually response to neuroprotective therapies.  
However, these indicators show lower levels in blood samples when compared to CSF, and 
highly sensitive immunochemical methods for their detection are needed. Importantly, recent 
studies have reported that tau and NF-L can be detected in blood (3, 9, 19, 21, 28, 29, 32, 38). 
To be able to define the reliability of these tests, different diseases and their combinations need 
to be examined. This was precisely our aim in this study and therefore we included cases with 
detailed neuropathological analysis.  
 
First we show that both tau and NF-L levels measured in the plasma reflect the results of the 
CSF examination, even if at a much lower concentrations. This is important since both are 
widely accepted markers of neuronal damage due to various aetiologies. Importantly, we 
demonstrate significant correlation of tau with NF-L levels both in plasma and CSF. Combined 
evaluation of tau and NF-L can be used as complementary examinations. The sensitivity and 
specificity of the blood tests are comparable to those of the CSF. In particular, high AUCs were 
detected when compared to controls, while lower when different disease groups were compared 
to each other. However, in latter comparisons disease groups contained a pool of individual 
cases with various molecular subtypes (i.e., sporadic CJD) or combined pathologies (i.e., AD 
with or without vascular lesions). Therefore, on an individual level both tau and NF-L may be 
suitable to support the diagnosis of a disorder with neuronal damage; however, further 
neuroimaging or CSF tests are still needed to be able to classify a disease. We show that the 
UmanDiagnostics assay is suitable for the quantification of NF-L in human plasma also, 
however, recent studies on CSF samples (23) indicate that it should be validated for each 
laboratory prior to application for routine diagnostics. 
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One major focus of our analyses was CJD. Human prion diseases belong to the most dramatic 
neurodegenerative disorders with rapid and prominent neuronal loss. However, these show 
different disease course based on molecular characteristics, which can be defined with the 
examination of PRNP gene together with brain tissue usually post mortem (26). Our 
observations in plasma support the importance of total tau levels (35) to distinguish CJD from 
controls, but also from AD or other disorders with neuronal damage. In concordance with other 
reports (8, 10), we show, however, that the molecular subtypes of sporadic CJD might be 
associated with different levels of total tau and NF-L. This is compatible with the observations 
of longer duration of illness for example in MV type 2 cases (26). Indeed, sporadic CJD 
subtypes are both qualitatively and regionally distinct in the predominance of neuronal death 
markers, confirming regional vulnerabilities of sporadic CJD subtypes that potentially reflect 
distinct responses to pathogenic events (17). Interestingly, the lowest tau and NF-L levels have 
been detected in a patient with variably protease-sensitive prionopathy (VPSPr) treated with 
doxycycline and showing nearly five years duration of illness (2). VPSP is a neurodegenerative 
disorder with spongiform encephalopathy and an unusual immunostaining and immunoblotting 
pattern for the disease-associated PrP with long duration of disease (39). We show that the time 
interval between sampling and death correlates inversely with plasma tau levels and less with 
NF-L. Therefore, plasma tau level can be discussed also as a potential prognostic factor both in 
AD and CJD. This will be appreciated when therapies are available and rapid and easy blood 
tests are at disposal, which can be used for follow-up as well. It must be noted, that, our cohort 
included various disorders, including molecular subtypes, while for homogenous disease 
groups NF-L levels can be also used to predict clinical outcome (32).  
 
The Braak stage of neurofibrillary degeneration or Lewy body pathology did not show a strong 
effect on the tau levels. This is not contrary to findings in AD that cognitive impairment seems 
to correlate best with the burden of neocortical neurofibrillary tangles (24), but rather suggests 
that tau and NF-L levels (i.e. plasma and CSF) reflect a relatively constant progression level of 
neuronal damage in AD. Higher values can be related to additional neuronal damage such as 
vascular lesions. Our study indicates, that inflammation, especially associated with prominent 
neuronal damage or hypoxic/ischemic brain damage, also associates with higher NF-L and tau 
levels. These disorders usually do not pose differential diagnostic issues for CJD or AD (i.e. 
increase cell counts), however, our observations further support the prognostic value of tau and 





Our neuropathology-based study shows that plasma tau and NF-L levels reflect those in CSF 
and may be used to substitute them for example in studies where CSF sampling is not feasible. 
We show that the highest levels of tau can be detected in CJD, however, rare molecular subtypes 
may show lower levels. Thus, combined evaluation of the polymorphic codon 129 of the PRNP 
can be helpful to interpret these results. We demonstrate increased levels of tau and NF-L in 
AD as compared to controls. Unexpected higher levels can be observed in additional vascular 
lesions or inflammatory changes associated with neuronal damage. We are aware that the 
evaluation of plasma tau and NF-L levels alone will be not suitable to specifically diagnose a 
disease; however, due the practicability of the blood tests and their strong association with 
tissue lesioning they can reliably support the clinical practice for evaluating the degree and 
dynamics of neuronal damage. Finally, the extreme elevation of plasma tau, together with the 
constellation of clinical symptoms, might support the suspicion of human prion disease. 
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Table 1. Demographic and neuropathological data of the examined cases. 
AD: Alzheimer disease; sCJD and gCJD: sporadic and genetic Creutzfeldt-Jakob disease; 
OND: other neurological disorders; Co: clinically healthy controls; NFT: neurofibrillary tangle; 
LRP: Lewy-related pathology; Molpath: molecular pathological subtype; - indicates not 
applicable. 
 
Variable n/%/type OND AD sCJD gCJD Co Total 
Men n 16 5 28 9 9 67 
 % 64 23.8 43.1 42.9 50 44.7 
Women n 9 16 37 12 9 83 
 % 36 76.2 56.9 57.1 50 55.3 
Sum n 25 21 65 21 18 168 
Age Mean 67.6 77 69 60.8 73.7 69.3 
 Min 48 51 55 42 65 42 
 Max 89 89 85 79 81 89 
Vascular lesion n 8 11 1 0 - 20 
 % 32 52.4 1.5 0 - 15.2 
Inflammation n 7 1 0 0 - 8 
 % 28 4.8 0 0 - 6.1 
Tauopathy n 0 3 3 1 - 7 
 % 0 14.3 4.6 4.8 - 5.3 
Neoplasm n 5 1 0 0 - 6 
 % 20 4.8 0 0 - 4.5 
Braak NFT (n) 0 14 0 20 17 - 51 
 I 2 0 20 2 - 24 
 II 5 0 15 1 - 21 
 III 4 1 6 1 - 12 
 IV 0 3 3 0 - 6 
 V 0 7 0 0 - 7 
 VI 0 10 0 0 - 10 
Brak LRP (n) 0 22 16 62 20 - 120 
 1 0 0 0 0 - 0 
 2 1 0 2 1 - 4 
 3 0 0 1 0 - 1 
 4 0 3 0 0 - 3 
 15 
 5 1 1 0 0 - 2 
 6 1 1 0 0 - 2 
Prion Molpath MM1 - - 34 - - 34 
 MM1+2 - - 7 - - 7 
 MM2 - - 3 - - 3 
 MV2K - - 6 - - 6 
 VV2 - - 10 - - 10 
 VV1 - - 4 - - 4 
  VPSPVV - - 1 - - 1 
Table 2. Spearman correlation test comparisons of cerebrospinal fluid and plasma tau and 
neurofilament levels. For the disease groups only the significant results are shown. R: 
correlation coefficient; AD: Alzheimer disease; CJD: Creutzfeldt-Jakob disease. 
 
Total cohort           
    CSF NF-L CSF Tau Plasma Tau NF-L Plasma 
CSF NF-L R - 0.42 0.161 0.69 
  p - <0.001 0.123 <0.001 
  N - 91 93 93 
CSF Tau R 0.42 - 0.59 0.34 
  p <0.001 - <0.001 0.001 
  N 91 - 91 91 
Plasma Tau R 0.161 0.59 - 0.50 
  p 0.123 <0.001 - <0.001 
  N 93 91 - 150 
NF-L Plasma R 0.69 0.34 0.50 - 
  p <0.001 0.001 <0.001 - 
  N 93 91 150 - 
Other neurological diseases       
    CSF NF-L CSF Tau Plasma Tau NF-L Plasma 
CSF NF-L R - 0.474 0.373 0.83 
  p - 0.064 0.141 <0.001 
  N - 16 17 17 
AD           
    CSF NF-L CSF Tau Plasma Tau NF-L Plasma 
CSF NF-L R - 0.71 0.06 0.54 
  p - 0.004 0.829 0.045 
  N - 14 14 14 
Sporadic CJD           
    CSF NF-L CSF Tau Plasma Tau NF-L Plasma 
CSF NF-L R - 0.34 -0.004 0.57 
  p - 0.02 0.981 0 
  N - 45 46 46 
CSF Tau R 0.34 - 0.51 0.33 
  p 0.02 - <0.001 0.025 
  N 45 - 45 45 
Plasma Tau R -0.004 0.51 - 0.33 
  p 0.981 <0.001 - 0.007 
  N 46 45 - 65 
NF-L Plasma R 0.57 0.33 0.33 - 
  p <0.001 0.025 0.007 - 
 16 
  N 46 45 65 - 
Genetic CJD           
    CSF NF-L CSF Tau Plasma Tau NF-L Plasma 
CSF NF-L R - 0.028 -0.152 0.50 
  p - 0.918 0.575 0.044 
  N - 16 16 16 
CSF Tau R 0.028 - 0.52 0.224 
  p 0.918 - 0.039 0.405 
  N 16 - 16 16 
 
 
Table 3. Area under the curve (AUC) values and 95% confidence intervals (CI) for Receiver-
Operating-Characteristic curves for the evaluation of plasma and cerebrospinal fluid (CSF) tau 
and neurofilament (NF-L) levels. AD: Alzheimer disease; CJD: Creutzfeldt-Jakob disease (s: 
sporadic, g: genetic); OND: other neurological disorder. 
 




Comparison AUC 95% CI   AUC 95% CI   AUC 95% CI   AUC 95% CI 
sCJD-AD 0.756 0.63-0.87 0.657 0.48-0.83 0.894 0.78-1.0   0.768 0.60-0.93 
sCJD-OND 0.722  0.60-0.83 0.497 0.30-0.69 0.883 0.78-0.98   0.451 0.27-0.63 
sCJD-gCJD 0.57 0.43-0.71 0.467 0.33-0.60 0.515 0.36-0.66   0.676 0.53-0.81 
gCJD-AD 0.694 0.53-0.85 0.705 0.50-0.90 0.902 0.77-1.0   0.862 0.71-1.0 
gCJD-OND 0.651 0.48-0.81 0.520 0.30-0.87 0.901 0.79-1.0   0.570 0.36-0.77 
AD-OND 0.453 0.28-0.62 0.441 0.27-0.61 0.429 0.21-0.63   0.759 0.58-0.93 
sCJD-CO 0.939 0.89-0.98 0.992 0.98-1.0   0.979 0.93-1.0   0.979 0.95-1.0 
gCJD-CO 0.918 0.83-1.0   1.0 1.0-1.0   1.0 1.0-1.0   0.997 0.98-1.0 
AD-CO 0.821 0.69-0.95 0.992 0.97-1.0   0.720 0.52-0.92   0.817 0.66-0.97 





















Legend to figures 
 
Figure 1.Scatter plots of plasma tau (A, E), NF-L (C, G) and CSF tau (B, F) and NF-L (D, H) 
in all disease groups examined (A-D) and in molecular subtypes of sporadic CJD (E-H). 
Horizontal lines in each plot for each disease group indicate the mean value observed for that 
group. The horizontal line spanning the whole graph area in E-H represents the mean values for 
the total cohort of sporadic CJD. * indicates p< 0.05; **: p< 0.01; ***: p<0.001; OND: other 
neurological disorder; AD: Alzheimer disease; sCJD: sporadic Creutzfeldt-Jakob disease; 
gCJD: genetic CJD, CO: healthy controls.  
 
 
Figure 2. Receiver operator characteristic curves and area under the curve (AUC) values for 
plasma tau examination for A) Alzheimer disease, B) sporadic CJD, C) genetic CJD, and D) 
other neurological disease versus healthy controls.  
 
